Sustained suppression of pituitary‐gonadal axis with an injectable, in situ forming implant of leuprolide acetate
- 1 June 2000
- journal article
- research article
- Published by Elsevier in Journal of Pharmaceutical Sciences
- Vol. 89 (6) , 732-741
- https://doi.org/10.1002/(sici)1520-6017(200006)89:6<732::aid-jps4>3.0.co;2-d
Abstract
No abstract availableKeywords
This publication has 11 references indexed in Scilit:
- Comparison of LH-RH Analogue 1-Month Depot and 3-Month Depot by Their Hormone Levels and Pharmacokinetic Profile in Patients with Advanced Prostate CancerUrologia Internationalis, 1998
- Biodegradable Microspheres in Drug DeliveryCritical Reviews in Therapeutic Drug Carrier Systems, 1995
- LeuprorelinDrugs, 1994
- Sustained Pharmacological Activities in Rats Following Single and Repeated Administration of Once-a-Month Injectable Microspheres of Leuprolide AcetatePharmaceutical Research, 1991
- Pharmacokinetics of Once-a-Month Injectable Microspheres of Leuprolide AcetatePharmaceutical Research, 1991
- Clinical Study of Leuprolide Depot Formulation in the Treatment of Advanced Prostate CancerJournal of Urology, 1990
- HPLC of Leuprolide Acetate in Injectable SolutionsJournal of Liquid Chromatography, 1987
- Leuprolide versus Diethylstilbestrol for Metastatic Prostate CancerNew England Journal of Medicine, 1984
- Potential new treatment of endometriosis: reversible inhibition of pituitary-ovarian function by chronic intranasal administration of a luteinizing hormone-releasing hormone (LH-RH) agonistFertility and Sterility, 1982
- Inhibition of prostate tumor growth in two rat models by chronic administration of D-Trp6 analogue of luteinizing hormone-releasing hormone.Proceedings of the National Academy of Sciences, 1981